Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574548 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
NCT00574548 is a Phase 3 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 720 participants.
The verdict
NCT00574548, a Phase 3 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
Study Summary
The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.
Interventions
- BIOLOGICAL 13 valent Pneumococcal Conjugate Vaccine
- BIOLOGICAL 23-valent Pneumococcal Polysaccharide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574548
The ClinicalTrials.gov registry entry for NCT00574548 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 13 valent Pneumococcal Conjugate Vaccine is the first listed.
NCT00574548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574548 about?
NCT00574548 is a clinical study titled "Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS". The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.
What is the current status of trial NCT00574548?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2007-11. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00574548?
The interventions under investigation include: 13 valent Pneumococcal Conjugate Vaccine (BIOLOGICAL), 23-valent Pneumococcal Polysaccharide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00574548?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.